Vyne Therapeutics Inc (VYNE) — Cash Flow-to-Debt Ratio
Vyne Therapeutics Inc (VYNE) has a Cash Flow-to-Debt Ratio of -1.57x as of December 2025, meaning its operating cash flow of $-3.76 Million could theoretically repay -2% of its total liabilities ($2.40 Million) in one year. Explore VYNE long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Vyne Therapeutics Inc Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Vyne Therapeutics Inc across 11 annual periods. Also explore VYNE total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Vyne Therapeutics Inc (2015–2025)
Year-by-year debt coverage analysis for Vyne Therapeutics Inc. For market capitalisation and broader financial context, see Vyne Therapeutics Inc stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -13.83x | $-33.12 Million | $2.40 Million | ▼ -503.3% |
| 2024 | -2.29x | $-33.97 Million | $14.82 Million | ▲ +19.0% |
| 2023 | -2.83x | $-25.34 Million | $8.95 Million | ▲ +7.3% |
| 2022 | -3.06x | $-29.20 Million | $9.56 Million | ▲ +0.2% |
| 2021 | -3.06x | $-56.37 Million | $18.41 Million | ▼ -25.6% |
| 2020 | -2.44x | $-137.08 Million | $56.25 Million | ▲ +60.1% |
| 2019 | -6.11x | $-65.10 Million | $10.66 Million | ▼ -10.6% |
| 2018 | -5.52x | $-52.73 Million | $9.55 Million | ▼ -2321.8% |
| 2017 | -0.23x | $-28.25 Million | $123.90 Million | ▼ -611.4% |
| 2016 | -0.03x | $-2.29 Million | $71.49 Million | ▲ +54.2% |
| 2015 | -0.07x | $-4.18 Million | $59.84 Million | — |